genedrive plc (FRA:D6M)

Market Cap	24.39M +322.6%
Revenue (ttm)	1.35M +91.5%
Net Income	-6.12M
EPS	-0.01
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.0105
Previous Close	0.0105
Day's Range	0.0105 - 0.0105
52-Week Range	0.0005 - 0.0225
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Dec 4, 2026

About genedrive

genedrive plc engages in the design, development, and manufacture of molecular diagnostics testing equipment for use in genotyping, pathogen detection, infectious disease detection, and other clinical indications. The company provides Genedrive system, rapid nucleic acid thermocycler and fluorescence signal detection system for target discrimination used for qualitative in vitro molecular diagnostic tests; and Genedrive CYP2C19 ID Kit, a certified test for identification of individuals unlikely to respond to the commonly prescribed antiplatelet...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2000
• Employees: 43
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: D6M

Financial Performance

In fiscal year 2025, genedrive's revenue was 954,000, an increase of 90.42% compared to the previous year's 501,000. Losses were -5.23 million, -26.06% less than in 2024.

Financial numbers in GBP

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 27, 2026

Data Sources Report a data error